Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2012-10-29
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01658176
Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 110
- Registration Number
- NCT01655004
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- Tianjin Medical University
- Target Recruit Count
- 600
- Registration Number
- NCT01648608
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China
Exemestane-RAD001-Metformin
- Conditions
- Interventions
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT01627067
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-06-22
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 301
- Registration Number
- NCT01626222
- Locations
- 🇩🇪
Novartis Investigative Site, Wuppertal, Germany
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)
- Conditions
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT01605396
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 101
- Registration Number
- NCT01597193
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Tennessee Oncology, PLLC., Nashville, Tennessee, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT01594398
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 25
- Registration Number
- NCT01594216
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not
- Conditions
- Interventions
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 29
- Registration Number
- NCT01553903
- Locations
- 🇫🇷
Institut Claudius REGAUD, Toulouse, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.